Macarena De La Fuente, MD
The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.
Inclusion Criteria: 1. Patient must be ≥18 years of age. 2. Patients with newly-diagnosed Glioblastoma (GBM) for whom neurosurgical tumor resection is indicated and planned according to the assessment of the treating physician as per treating physician or neurosurgeon. 3. Patient must have Karnofsky Performance Status (KPS) ≥ 70. 4. Magnetic resonance imaging (MRI) scan performed within 21 days prior to starting protocol treatment. 5. For women (any individual assigned female at birth) who are not postmenopausal (i.e., \< 2 years after last menstruation) or surgically sterile (absence of ovar…
Participants will receive Lixumistat 400 mg administered orally once daily for up to four days prior to surgery. If the surgical procedure is delayed by up to two days, dosing may continue for a maximum total of six days.
Participants will receive Lixumistat 600 mg administered orally once daily for up to four days prior to surgery. If the surgical procedure is delayed by up to two days, dosing may continue for a maximum total of six days.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.